Résumé :
|
[BDSP. Notice produite par INIST-CNRS a4R0xShm. Diffusion soumise à autorisation]. Context The association between menopausal hormone replacement therapy and ovarian cancer is unclear. Objective To determine whether hormone replacement therapy using estrogen only, estrogen-progestin only, or both estrogen only and estrogen-progestin increases ovarian cancer risk. Design A 1979-1998 cohort study of former participants in the Breast Cancer Detection Demonstration Project, a nationwide breast cancer screening program. Setting Twenty-nine US clinical centers. Participants A total of 44241 postmenopausal women (mean age at start of follow-up, 56.6 years). Main Outcome Measure Incident ovarian cancer. Results We identified 329 women who developed ovarian cancer during follow-up. In time-dependent analyses adjusted for age, menopause type, and oral contraceptive use, ever use of estrogen only was significantly associated with ovarian cancer (rate ratio [RR], 1.6 ; 95% confidence interval [Cl], 1.2-2.0). Increasing duration of estrogen-only use was significantly associated with ovarian cancer : RRs for 10 to 19 years and 20 or more years were 1.8 (95% Cl, 1.1-3.0) and 3.2 (95% Cl, 1.7-5.7), respectively (P value for trend<. and we observed a cl increase in rr per year of use. significantly elevated rrs with increasing duration estrogen-only use across all strata other ovarian cancer risk factors including women hysterectomy. the for estrogen-progestin after prior was but estrogen-progestin-only less than years or more were respectively there no evidence response value trend="30)." conclusion who used replacement therapy particularly at increased this study. short-term not associated longer-term warrants further investigation.>
|